Minimal residue disease (MRD) in multiple myeloma
What’s next for rare myelomas?
Increased risk of myeloma in rescue workers exposed to smoke and toxins after 9/11
The Phase II clinical trial of ixazumib, the first oral proteasome inhibitor in MM
Is CLL curable today?